Valeska Andreozzi

Valeska Andreozzi

Auto-generated profile, based on publicly available information

Valeska Andreozzi

Exigo Consultores, Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Appetite
Verified
Journal Article
Closed access
Catarina DurãoCatarina Durão
Catarina Durão
VAValeska Andreozzi
Valeska Andreozzi
AOAndreia Oliveira
Andreia Oliveira
Pedro MoreiraPedro Moreira
Pedro Moreira
AGAntónio Guerra
António Guerra
CLCarla Lopes
Carla Lopes

14 March 2016 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
RMRui Martins
Rui Martins
GSGiovani Silva
Giovani Silva
VAValeska Andreozzi
Valeska Andreozzi


4 April 2007 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
João Eurico FonsecaJoão Eurico Fonseca
João Eurico Fonseca
JCJoão Cavaleiro
João Cavaleiro
JTJosé Teles
José Teles
ESElsa Sousa
Elsa Sousa
VAValeska L Andreozzi
Valeska L Andreozzi
MQMário Viana Queiroz
Mário Viana Queiroz
The objective of this study was to assess whether clinical measures of rheumatoid arthritis activity and severity were influenced by tumor necrosis factor-alpha (TNF-α) promoter genotype/haplotype markers. Each patient's disease activity was assessed by the disease activity score using 28 joint counts (DAS28) and functional capacity by the Health Assessment Questionnaire (HAQ) score. Systemic manifestations, radiological damage evaluated by the Sharp/van der Heijde (SvdH) score, disease-modifying anti-rheumatic drug use, joint surgeries, and work disability were also assessed. The promoter region of the TNF-α gene, between nucleotides -1,318 and +49, was sequenced using an automated platform. Five hundred fifty-four patients were evaluated and genotyped for 10 single-nucleotide polymorphism (SNP) markers, but 5 of these markers were excluded due to failure to fall within Hardy-Weinberg equilibrium or to monomorphism. Patients with more than 10 years of disease duration (DD) presented significant associations between the -857 SNP and systemic manifestations, as well as joint surgeries. Associations were also found between the -308 SNP and work disability in patients with more than 2 years of DD and radiological damage in patients with less than 10 years of DD. A borderline effect was found between the -238 SNP and HAQ score and radiological damage in patients with 2 to 10 years of DD. An association was also found between haplotypes and the SvdH score for those with more than 10 years of DD. An association was found between some TNF-α promoter SNPs and systemic manifestations, radiological progression, HAQ score, work disability, and joint surgeries, particularly in some classes of DD and between haplotypes and radiological progression for those with more than 10 years of DD.


8 September 2022 in GE - Portuguese Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
RSRaul Silva
Raul Silva
PGPaula Guerra
Paula Guerra
ARAnabela Rocha
Anabela Rocha
MCMiguel Correia
Miguel Correia
RFRicardo Ferreira
Ricardo Ferreira
MSMarisa Domingues Santos
Marisa Domingues Santos
Introduction: This study aimed to assess the clinical, economic, and humanistic impact of short-bowel syndrome/chronic intestinal failure (SBS/CIF) in Portugal. Methods: This is a retrospective multicenter cohort chart review study, with a cross-sectional component for quality-of-life (QoL) evaluation. Inclusion criteria comprised patients with SBS/CIF, aged ≥1 year, with stable parenteral nutrition (PN). Data collection included patient chart review over a 12-month period and patient/caregiver self-report and SF-36/PedsQL™ questionnaires. Main endpoints comprised clinical and PN characterization, healthcare resource use (HRU), direct costs, and patient QoL. Results: Thirty-one patients were included (11 adults and 20 children). Patients’ mean age (standard deviation [SD]) was 57.9 (14.3) years in adults and 7.5 (5.0) years in children, with a mean time since diagnosis of 10.2 (5.9) and 6.6 (4.2) years, respectively. PN was administered for a mean of 5.2 and 6.6 days/week in adults and children, respectively; home PN occurred in 81.8% of adults and 90.0% of children for a mean of 9.6 and 10.8 months/year, respectively. The mean annual number of hospitalizations was 1.9 and 2.0 which lasted for a mean of 34.0 and 29.4 days in adults and children, respectively. Twenty-one and forty hospitalization episodes were reported in adults and children, respectively, of which 71.4% and 85.0% were due to catheter-related complications. Mean annual direct costs per patient amounted to 47,857.53 EUR in adults and 74,734.50 EUR in children, with PN and hospitalizations as the main cost-drivers. QoL assessment showed a clinically significant impaired physical component in adults and a notable deterioration in the school functioning domain in children. Conclusion: In Portugal, SBS/CIF patient management is characterized by a substantial therapeutic burden and HRU, translating into high direct costs and a substantial impairment of the adults’ physical function and children’s school functioning.